European Non-Compliance Report on Data Integrity
Recommendation

24-27 November 2026
The results of inspections performed by the European authorities are published in the EudraGMDP database. Negative results can be found in the "Non-Compliance Reports" area - see our News "Already 13 EMA GMP Non-compliance Reports in 2016 published".
On 17 March.2016, the British authority MHRA published a Non Compliance Report against the Indian company Marksans Pharma Limited. The report lists serious problems with regard to data integrity.
A number of serious violations of the pharmaceutical quality system had already been observed during a first inspection performed in March 2015. These violations related to the systems assuring data integrity, deviation and CAPA management, change control, PQRs and self-inspections. During a re-inspection in November 2015, the inspector noticed that many of the violations observed hadn't been processed. Among other things, the critical violations with regard to the systems assuring data integrity were still present:
- Evidence of destruction of multiple parts of records of prime data
- Overall Data Integrity management and oversight
- Investigations into Missing and deleted data within laboratory incomplete
- Procedures controlling Data Integrity within the laboratory not in place
As a consequence for the company, comprehensive measures have been imposed until the Non Compliance Report is worked out:
- Withdrawal of previous GMP Certificate No. ...
- No further marketing authorisation(s) should be approved naming the site as manufacturer
- No further batches of medicinal products considered non-critical to public health to be supplied to the market whilst this statement of non-compliance remains in force
Source: Overview of all EudraGMDP non compliance reports
Related GMP News
02.11.2026FDA Warning Letter: When Test Procedures Allow Retesting Until an Acceptable Result is Obtained
21.10.2026EMA Updates Information Page on Bioequivalence Guidelines
21.10.2026BP Publishes new Draft Texts
21.10.2026FDA Identifies Critical Deficiencies in Analytical Testing and CGMP Oversight
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
